Orphai Therapeutics Inc. (“Orphai”), a clinical-stage biopharmaceutical company dedicated to advancing novel therapeutics for patients with diseases of significant unmet need, today announced that ...
Poster (1330P): Phase 2 Study of Pembrolizumab (Pemb) plus Plinabulin (Plin) and Docetaxel (Doc) for Patients (pts) with Metastatic NSCLC after Failure on First-line Immune Checkpoint Inhibitor Alone ...
HepQuant, a leader in developing noninvasive, blood-based, quantitative testing to assess liver health, presented oral and ...
IDEAYA will also have a poster presentation with data from a second published abstract providing combination mechanism and pre-clinical synergy data between TOP1-payload based ADCs and IDE161, the ...
Faculty and students from the U of A 's apparel merchandising and product development program attended the International Textile and Apparel Association (ITAA) Annual Conference in St. Louis, Missouri ...
CAMBRIDGE, Mass., Sept. 17, 2025 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), developing innovative cell therapies for the treatment of advanced cancer and autoimmune disease, today ...
MIPLYFFA (arimoclomol) is Zevra’s approved therapy for the treatment of Niemann-Pick disease type C (NPC). Approved by the U.S. Food and Drug Administration on Sep. 20, 2024, MIPLYFFA (arimoclomol) ...
CARY, N.C. — January 7, 2026 — INDA, the Association of the Nonwoven Fabrics Industry, in partnership with AFS, the American ...
DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing ...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic ...
Presenters: John Alam, MD, CEO of CervoMed and Co-Principal Investigator of the RewinD-LB Study and Stephen Gomperts, MD, PhD, Associate Professor of Neurology at Harvard Medical School and Director, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback